AU2017258901A1 — Methods for predicting drug responsiveness in cancer patients
Assigned to Allarity Therapeutics Europe ApS · Expires 2018-07-19 · 8y expired
What this patent protects
METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS The present invention features methods, devices, and kits for detecting a level of one or more 5 biomarkers in a patient having cancer or determining the responsiveness of a patient having cancer to a treatment, such a…
USPTO Abstract
METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS The present invention features methods, devices, and kits for detecting a level of one or more 5 biomarkers in a patient having cancer or determining the responsiveness of a patient having cancer to a treatment, such as treatment with a secretory phospholipase A2 (sPLA2) hydrolysable, cisplatin-containing liposome. The invention further includes methods of treating a patient having cancer by administering, e.g., the liposome. Predicted sensitivity 0 20 40 60 80 100 AML - ED CLL -- MM - SIM WM - CD EM MDS - ooCm DLBCL - o -m CTCL - o IJSIZnmaaInn- - so Hodgkin -- HCC - o-@IH Cervix - EMmD-G Prosta RCC - -e Eso - e- ~ xm - -------------- o Melan Glioma - m - m Pancreas - o -se ------ e a oo Ovary - (M e D-o GIST -e ei105 Sarcoma Breast - e-cwe ERpos -- NSCLC - o--0 _____ - E Colon - 0wM- -use- --e e- o Bladder - ocm SCCHN - x@ >- - Page 1 / 1
Drugs covered by this patent
- Camptosar (Irinotecan Hydrochloride) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.